JP5386508B2 - インドリル−ピリドン誘導体類 - Google Patents

インドリル−ピリドン誘導体類 Download PDF

Info

Publication number
JP5386508B2
JP5386508B2 JP2010543556A JP2010543556A JP5386508B2 JP 5386508 B2 JP5386508 B2 JP 5386508B2 JP 2010543556 A JP2010543556 A JP 2010543556A JP 2010543556 A JP2010543556 A JP 2010543556A JP 5386508 B2 JP5386508 B2 JP 5386508B2
Authority
JP
Japan
Prior art keywords
title compound
carboxylic acid
oxo
dihydro
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010543556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510055A (ja
JP2011510055A5 (OSRAM
Inventor
ストークス，スティーブン
フォロップ，ニコラ
フィウマーナ，アンドレア
ドライスデール，マーティン
ベッドフォード，サイモン
ウェッブ，ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0801090.2A external-priority patent/GB0801090D0/en
Priority claimed from GBGB0818695.9A external-priority patent/GB0818695D0/en
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Publication of JP2011510055A publication Critical patent/JP2011510055A/ja
Publication of JP2011510055A5 publication Critical patent/JP2011510055A5/ja
Application granted granted Critical
Publication of JP5386508B2 publication Critical patent/JP5386508B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010543556A 2008-01-22 2009-01-20 インドリル−ピリドン誘導体類 Expired - Fee Related JP5386508B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0801090.2 2008-01-22
GBGB0801090.2A GB0801090D0 (en) 2008-01-22 2008-01-22 New chemical compounds
GBGB0818695.9A GB0818695D0 (en) 2008-10-11 2008-10-11 New chemical compounds
GB0818695.9 2008-10-11
PCT/GB2009/000149 WO2009093012A1 (en) 2008-01-22 2009-01-20 Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity

Publications (3)

Publication Number Publication Date
JP2011510055A JP2011510055A (ja) 2011-03-31
JP2011510055A5 JP2011510055A5 (OSRAM) 2012-03-01
JP5386508B2 true JP5386508B2 (ja) 2014-01-15

Family

ID=40377594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010543556A Expired - Fee Related JP5386508B2 (ja) 2008-01-22 2009-01-20 インドリル−ピリドン誘導体類

Country Status (17)

Country Link
US (5) US8916591B2 (OSRAM)
EP (1) EP2294065B1 (OSRAM)
JP (1) JP5386508B2 (OSRAM)
CN (1) CN101970424B (OSRAM)
AU (1) AU2009207478B2 (OSRAM)
BR (1) BRPI0906495B8 (OSRAM)
CA (1) CA2712959C (OSRAM)
DK (1) DK2294065T3 (OSRAM)
EA (1) EA021464B1 (OSRAM)
ES (1) ES2461799T3 (OSRAM)
IL (1) IL206808A (OSRAM)
MX (1) MX2010007525A (OSRAM)
NZ (1) NZ586756A (OSRAM)
PL (1) PL2294065T3 (OSRAM)
PT (1) PT2294065E (OSRAM)
WO (1) WO2009093012A1 (OSRAM)
ZA (1) ZA201005210B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5386508B2 (ja) 2008-01-22 2014-01-15 ヴァーナリス アールアンドディー リミテッド インドリル−ピリドン誘導体類
GB0912499D0 (en) * 2009-07-18 2009-08-26 Vernalis R&D Ltd Indopyl-pyridone derivatives
CN102933572B (zh) 2010-04-07 2015-01-07 霍夫曼-拉罗奇有限公司 吡唑-4-基-杂环基-甲酰胺化合物及其使用方法
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
BR112014007203A2 (pt) 2011-09-27 2017-06-13 F.Hoffmann-La Roche Ag composto, composição farmacêutica, método de tratamento, utilização de um composto, conjunto e invenção
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
CR20170345A (es) * 2015-01-28 2017-09-29 Bayer Pharma Aktiengesellchaft Derivados de 4h-pirrol[3,2-c]piridin-4-ona
SG11202005700SA (en) * 2017-12-19 2020-07-29 Bristol Myers Squibb Co Amide substituted indole compounds useful as tlr inhibitors
KR20210038911A (ko) * 2018-07-24 2021-04-08 에피자임, 인코포레이티드 Smarca2 길항제로서 유용한 피리딘-2-온 화합물
US10253606B1 (en) 2018-07-27 2019-04-09 Upwing Energy, LLC Artificial lift
US10280721B1 (en) 2018-07-27 2019-05-07 Upwing Energy, LLC Artificial lift
US10787873B2 (en) 2018-07-27 2020-09-29 Upwing Energy, LLC Recirculation isolator for artificial lift and method of use
US10370947B1 (en) * 2018-07-27 2019-08-06 Upwing Energy, LLC Artificial lift
WO2020038460A1 (zh) * 2018-08-24 2020-02-27 南京药捷安康生物科技有限公司 一种新型的喹啉衍生物抑制剂
US11686161B2 (en) 2018-12-28 2023-06-27 Upwing Energy, Inc. System and method of transferring power within a wellbore
EP4036086A1 (en) * 2019-09-24 2022-08-03 Transthera Sciences (Nanjing), Inc. Heterocyclic derivative and use thereof
JP2025523514A (ja) * 2022-06-24 2025-07-23 エナラーレ セラピューティクス インコーポレイテッド 神経性換気不全の処置方法
CN115594634B (zh) * 2022-10-26 2024-10-01 浙江工业大学 一种连续化制备4-硝基吡唑的新工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20030844A2 (en) * 2001-03-28 2005-08-31 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
EP1441725A1 (en) 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
JP2006526654A (ja) 2003-06-05 2006-11-24 メルク　エンド　カムパニー　インコーポレーテッド 置換インドールおよび置換インドールの調製方法
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
WO2007084135A2 (en) * 2005-01-28 2007-07-26 Merck & Co., Inc. Inhibitors of checkpoint kinases
EP1891048A1 (en) * 2005-06-11 2008-02-27 Vernalis (R&D) Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
WO2008007122A2 (en) * 2006-07-14 2008-01-17 Astex Therapeutics Limited Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
WO2008025526A1 (en) 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Indole derivatives, their manufacture and use as pharmaceutical agents
JP5386508B2 (ja) 2008-01-22 2014-01-15 ヴァーナリス アールアンドディー リミテッド インドリル−ピリドン誘導体類
US8778972B2 (en) * 2009-05-15 2014-07-15 Novartis Ag 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1

Also Published As

Publication number Publication date
US20200361905A1 (en) 2020-11-19
PT2294065E (pt) 2014-05-15
IL206808A0 (en) 2010-12-30
EP2294065A1 (en) 2011-03-16
CA2712959C (en) 2015-06-23
EP2294065B1 (en) 2014-03-19
BRPI0906495A2 (pt) 2015-07-14
NZ586756A (en) 2012-04-27
DK2294065T3 (da) 2014-04-28
AU2009207478B2 (en) 2013-11-21
BRPI0906495B8 (pt) 2021-05-25
US20180244652A1 (en) 2018-08-30
AU2009207478A1 (en) 2009-07-30
CA2712959A1 (en) 2009-07-30
US20110021498A1 (en) 2011-01-27
MX2010007525A (es) 2010-08-18
US8916591B2 (en) 2014-12-23
EA201001197A1 (ru) 2011-04-29
WO2009093012A1 (en) 2009-07-30
CN101970424B (zh) 2013-06-12
US9604975B2 (en) 2017-03-28
US20170298043A1 (en) 2017-10-19
ZA201005210B (en) 2011-03-30
US20150099736A1 (en) 2015-04-09
CN101970424A (zh) 2011-02-09
IL206808A (en) 2015-08-31
EA021464B1 (ru) 2015-06-30
JP2011510055A (ja) 2011-03-31
US10696652B2 (en) 2020-06-30
PL2294065T3 (pl) 2014-11-28
ES2461799T3 (es) 2014-05-21
BRPI0906495A8 (pt) 2015-10-06
BRPI0906495B1 (pt) 2020-11-10

Similar Documents

Publication Publication Date Title
JP5386508B2 (ja) インドリル−ピリドン誘導体類
CN114867720B (zh) 杂芳基类衍生物及其制备方法和用途
CN106170288B (zh) 药物化合物
CN114761086A (zh) 作为parp7抑制剂的哒嗪酮
CN115697990A (zh) 基于吲唑的化合物和相关使用方法
CN102471314B (zh) 适合于特别是睡眠障碍和药物成瘾的治疗的螺氨基化合物
KR20120097410A (ko) 베타－트립타제 억제제로서의 인돌릴－피페리디닐 벤질아민
TW202322811A (zh) Parp-1降解劑及其用途
KR20230173234A (ko) 인다졸계 화합물 및 관련된 사용 방법
WO2022166974A1 (zh) 吡啶并嘧啶酮类衍生物及其制备方法和用途
CN113968856A (zh) 一类具有激酶抑制活性的化合物
EP3083597B1 (en) Fluoromethyl-substituted pyrrole carboxamides as cav2.2 calcium channel blockers
WO2024151638A2 (en) Compounds for fgfrs inhibitors
CN120835881A (zh) 能够降解雄激素受体的双官能化合物
CN116917279A (zh) Btk抑制剂
CN100436445C (zh) 吡唑衍生物
CN117430589A (zh) 2-氨基嘧啶类化合物或其盐及其制备方法和用途
WO2025034912A9 (en) Compounds for fgfr inhibition
WO2011010083A1 (en) Indolyl-pyridone derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131007

R150 Certificate of patent or registration of utility model

Ref document number: 5386508

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees